PNAGPoly-N-Acetyl Glucosamine (antigen)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
- US-based vaccine developer Alopexx Vaccine LLC has completed a Phase 1 clinical trial with AV0328, a vaccine targeting the broadly expressed microbial antigen, poly-N-acetyl glucosamine (PNAG), the company said.
PNAG, which is expressed on the surface of various bacteria, fungi and protozoan organisms, has been shown to be a critical factor in the virulence of many pathogens.
Antibodies to PNAG have the potential to prevent many serious and life-threatening infections such as pneumonia, meningitis, bloodstream infections, gonorrhea, and also those caused by antibiotic resistant bacteria such as MRSA.
In the run-up to the 2000 presidential election, PNAG published a report, "Rebuilding America's Defenses" which has served as a blueprint for the Bush-Rumsfeld Pentagon military strategy, up to and including the coining of terms such as "regime change."
Le Plan nord-americain de gestion de la sauvagine (PNAGS) est un bel exemple de gestion des canards, des oies et des cygnes.
L'article propose un apercu du PNAGS, de son developpement et de ses orientations.